Tags

Type your tag names separated by a space and hit enter

Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection.
J Med Microbiol. 2004 May; 53(Pt 5):435-438.JM

Abstract

To understand the time-course of viraemia and antibody responses to severe acute respiratory syndrome-associated coronavirus (SARS-CoV), RT-PCR and ELISA were used to assay 376 blood samples from 135 SARS patients at various stages of the illness, including samples from patients who were in their early convalescent phase. The results showed that IgM antibodies decreased and became undetectable 11 weeks into the recovery phase. IgG antibodies, however, remained detectable for a period beyond 11 weeks and were found in 100 % of patients in the early convalescent phase. SARS-CoV viraemia mainly appeared 1 week after the onset of illness and then decreased over a period of 1 month, becoming undetectable in the blood samples of the convalescent patients. At the peak of viraemia, viral RNA was detectable in 75 % of blood samples from patients who were clinically diagnosed with SARS 1 or 2 weeks before the test.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Chen W
Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China.
Xu Z
Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China.
Mu J
Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China.
Yang L
Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China.
Gan H
Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China.
Mu F
Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China.
Fan B
Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China.
He B
Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China.
Huang S
Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China.
You B
Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China.
Yang Y
Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China.
Tang X
Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China.
Qiu L
Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China.
Qiu Y
Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China.
Wen J
Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China.
Fang J
Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China.
Wang J
Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300, China 2Beijing BGI-GBI Biotech Co. Ltd, Beijing 101300, China 3Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China 4Beijing 302 Hospital, Beijing 100039, China 5Beijing 301 Hospital, Beijing 100853, China 6Beijing Union Hospital, Beijing 100730, China 7Beijing Red Cross Blood Center, Beijing 100088, China.

MeSH

AdolescentAdultAgedAged, 80 and overAntibodies, ViralEnzyme-Linked Immunosorbent AssayFemaleHumansImmunoglobulin GImmunoglobulin MMaleMiddle AgedRNA, ViralReverse Transcriptase Polymerase Chain ReactionSevere acute respiratory syndrome-related coronavirusSevere Acute Respiratory SyndromeSeverity of Illness IndexViremia

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15096554

Citation

Chen, Weijun, et al. "Antibody Response and Viraemia During the Course of Severe Acute Respiratory Syndrome (SARS)-associated Coronavirus Infection." Journal of Medical Microbiology, vol. 53, no. Pt 5, 2004, pp. 435-438.
Chen W, Xu Z, Mu J, et al. Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection. J Med Microbiol. 2004;53(Pt 5):435-438.
Chen, W., Xu, Z., Mu, J., Yang, L., Gan, H., Mu, F., Fan, B., He, B., Huang, S., You, B., Yang, Y., Tang, X., Qiu, L., Qiu, Y., Wen, J., Fang, J., & Wang, J. (2004). Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection. Journal of Medical Microbiology, 53(Pt 5), 435-438. https://doi.org/10.1099/jmm.0.45561-0
Chen W, et al. Antibody Response and Viraemia During the Course of Severe Acute Respiratory Syndrome (SARS)-associated Coronavirus Infection. J Med Microbiol. 2004;53(Pt 5):435-438. PubMed PMID: 15096554.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection. AU - Chen,Weijun, AU - Xu,Zuyuan, AU - Mu,Jingsong, AU - Yang,Ling, AU - Gan,Haixue, AU - Mu,Feng, AU - Fan,Baoxing, AU - He,Bo, AU - Huang,Shengyong, AU - You,Bo, AU - Yang,Yongkui, AU - Tang,Xiangjun, AU - Qiu,Ling, AU - Qiu,Yan, AU - Wen,Jie, AU - Fang,Jianqiu, AU - Wang,Jian, PY - 2004/4/21/pubmed PY - 2004/6/2/medline PY - 2004/4/21/entrez SP - 435 EP - 438 JF - Journal of medical microbiology JO - J Med Microbiol VL - 53 IS - Pt 5 N2 - To understand the time-course of viraemia and antibody responses to severe acute respiratory syndrome-associated coronavirus (SARS-CoV), RT-PCR and ELISA were used to assay 376 blood samples from 135 SARS patients at various stages of the illness, including samples from patients who were in their early convalescent phase. The results showed that IgM antibodies decreased and became undetectable 11 weeks into the recovery phase. IgG antibodies, however, remained detectable for a period beyond 11 weeks and were found in 100 % of patients in the early convalescent phase. SARS-CoV viraemia mainly appeared 1 week after the onset of illness and then decreased over a period of 1 month, becoming undetectable in the blood samples of the convalescent patients. At the peak of viraemia, viral RNA was detectable in 75 % of blood samples from patients who were clinically diagnosed with SARS 1 or 2 weeks before the test. SN - 0022-2615 UR - https://www.unboundmedicine.com/medline/citation/15096554/Antibody_response_and_viraemia_during_the_course_of_severe_acute_respiratory_syndrome__SARS__associated_coronavirus_infection_ DB - PRIME DP - Unbound Medicine ER -